Announcements Trials
Browse Landscape

Phase

Phase 1 3Phase 2 1

Status

Completed 4Recruiting 1

Sponsor Class

INDUSTRY 4

Study Type

Interventional 4

Sponsor

Cancer Type

CNS 4

Conditions

Glioma 4Glioblastoma 4Astrocytoma 3Neoplasms 2Lung Neoplasms 2Leukemia, Lymphocytic, Chronic, B-Cell 2Epstein-Barr Virus Infections 2Breast Neoplasms 2Wilms Tumor 1Triple Negative Breast Neoplasms 1Testicular Neoplasms 1Sezary Syndrome 1Recurrence 1Primary Myelofibrosis 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Pleural Effusion, Malignant 1Pdgfra-Associated Chronic Eosinophilic Leukemia 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Neuroblastoma 1Myeloproliferative Disorders 1Mycosis Fungoides 1Multiple Myeloma 1Mesothelioma 1Lymphoma, T-Cell, Cutaneous 1Lymphoma, Non-Hodgkin 1Lymphoma, Mantle-Cell 1Lymphoma, Large-Cell, Immunoblastic 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, Follicular 1

Interventions

Temozolomide 203Radiotherapy 118Bevacizumab 93Radiation 40Magnetic Resonance Spectroscopy 28Irinotecan 27Carmustine 25Surgical Procedures, Operative 24Lomustine 21Erlotinib Hydrochloride 19Chemotherapy, Adjuvant 18Carboplatin 17temsirolimus 13Drug Therapy 13O(6)-benzylguanine 12Nivolumab 12sargramostim 11Sirolimus 11Radiotherapy, Intensity-Modulated 11Radiotherapy, Conformal 11Sorafenib 10Radiosurgery 10Imatinib Mesylate 10Everolimus 10pembrolizumab 9motexafin gadolinium 9Vorinostat 9Thalidomide 8IL13-PE38 8Gefitinib 8

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Completed × Glioblastoma × Valacyclovir × Clear all
NCT03576612 2025-02-14

GMCI

Candel Therapeutics, Inc.

Phase 1 Completed
41 enrolled
CNS

Glioblastoma, Glioma

NCT00589875 2024-04-03

BrTK02

Candel Therapeutics, Inc.

Phase 2 Completed
52 enrolled 10 charts
CNS

Astrocytoma, Glioblastoma, Glioma

NCT00634231 2023-08-25

A Phase I Study of AdV-tk + Prodrug Therapy in Combination With Radiation Therapy for Pediatric Brain Tumors

Candel Therapeutics, Inc.

Phase 1 Completed
8 enrolled
CNS

Astrocytoma, Ependymoma, Glioblastoma, Glioma

NCT00751270 2023-08-25

BrTK01

Candel Therapeutics, Inc.

Phase 1 Completed
15 enrolled
CNS

Astrocytoma, Glioblastoma, Glioma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡